Regenerative Stem cell therapy for Myocardial Infarction: MiRNA-518c improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 (Serine/threonine-protein phosphatase 1 regulatory subunit 10), 6/February/2015, 6.48 am
A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March 2013 issue of Nature by Prof Dimmler, Boon, and others. On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Regenerative Stem cell therapy for Myocardial Infarction: MiRNA-518c improves myocardial function after myocardial infarction via up regulation of PNUTS/PPP1R10 […]
MiRNA-based therapy for Cancer : MiRNA-125a-5p increases the expression of tumor suppressor INK4a/ARF via down regulation of its target gene, 5/March/2015, 22.45
Idea Proposed/Formulated by: Dr L Boominathan Ph.D. Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/ Web: http://genomediscovery.org Significance: This study suggests, for the first time, MiRNA-125a-5p, by suppressing the expression of its target gene, it may increase the expression of tumor suppressor INK4a/ARF. Thus, pharmacological formulations encompassing “MiRNA-125a-5p or its activators” can be used to inhibit the progression of human tumors. Web: http://genomediscovery.org Courtesy: When you cite drop […]
Mechanistic insights into mammary tumorigenesis: EMSY increases the expression of polycomb group (PcG) protein BMI1 and suppresses the expression of INK4a/ARF via down regulation of its target gene, 5/March/2015, 22.10
Idea Proposed/Formulated by: Dr L Boominathan Ph.D. Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/ Prof. Dr Kouzarides and his co-workers from Cancer Research Gurdon Institute, University of Cambridge, UK report in the prestigious journal Molecular Cell (2014) that “The Breast Cancer Oncogene EMSY Represses Transcription of Antimetastatic microRNA miR-31” On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Mechanistic insights into mammary […]
Molecular therapy for pulmonary hypertension: Nutlin suppresses pulmonary hypertension via up regulation of its target gene, 5/March/2015, 21.45
A recent study from the from the Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, United States of America shows that “High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4.“ This study was published in the 8 Feb’13 issue of the Journal “Molecular Medicine” by Drs. Bauer PM, Bauer EM and others. On […]
Natural product-based therapy for pulmonary hypertension: Curcumin, the major component of turmeric, suppresses pulmonary hypertension via up regulation of its target gene, 5/March/2015, 21.35
A recent study from the from the Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, United States of America shows that “High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4.“ This study was published in the 8 Feb’13 issue of the Journal Molecular Medicine by Drs. Bauer PM, Bauer EM and others. On […]
Interleukin-based anti-cancer therapy: Interleukin-37 (IL-37) increases the expression of TPM via down regulation of its target gene, 5/March/2015, 21.28
Idea Proposed/Formulated by: Dr L Boominathan Ph.D. Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/ Web: http://genomediscovery.org Significance: This study suggests, for the first time, Interleukin-37 (IL-37), by suppressing the expression of its target gene, it may increase the expression of tumor suppressor TPM. Thus, pharmacological formulations encompassing “IL-37 or its activators” can be used to inhibit the progression of human tumors. Citation: Boominathan, Interleukin-based anti-cancer therapy: Interleukin-37 (IL-37) […]